Corvus Pharmaceuticals (CRVS) Enterprise Value (2015 - 2026)

Corvus Pharmaceuticals' Enterprise Value history runs 12 years deep, the most recent figure standing at -$236.7 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 4635.23% year-over-year to -$236.7 million in Q1 2026; TTM through Mar 2026 was -$236.7 million, a 4635.23% decrease from a year earlier, with the FY2025 full-year figure at -$56.8 million, down 9.21% from the prior year.
• Enterprise Value slipped to -$236.7 million in Q1 2026 per CRVS's latest filing, from -$56.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$2.9 million in Q3 2025 and bottomed at -$236.7 million in Q1 2026.
• The 5-year median for Enterprise Value is -$14.7 million (2025), against an average of -$31.9 million.
• Across the five-year window, Enterprise Value surged 79.26% in 2022 and slumped 4635.23% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$13.2 million in 2022, then climbed by 4.1% to -$12.6 million in 2023, then sank by 311.76% to -$52.0 million in 2024, then slipped by 9.21% to -$56.8 million in 2025, then tumbled by 317.12% to -$236.7 million in 2026.
• Per Business Quant, the three latest CRVS Enterprise Value figures stand at -$236.7 million (Q1 2026), -$56.8 million (Q4 2025), and -$2.9 million (Q3 2025).